Medite Cancer Diagnostics, Inc. functions as a specialized medical technology enterprise focused on the development, manufacturing, and commercialization of molecular biomarkers, sophisticated medical devices, and consumables. These products are engineered for the detection, risk assessment, and precise diagnosis of cancerous, pre-cancerous, and related conditions. The company's diverse product portfolio includes a range of essential laboratory instruments: the USE 33, an ultrasonic decalcification instrument that operates automatically under controlled temperatures; the TPC 15 Duo and Trio for tissue processing; TES 99 and TES Valida cooling units; and microtomes such as the M530, A550, M380 for tissue sectioning, alongside the M630 freezing microtome. Additionally, Medite offers automated solutions for slide preparation, including the TST44 robotic multi-staining system, the COT 20 linear staining system, and robotic coverslippers like the RCM 9000, ACS 720, and TWISTER. A notable innovation is the SoftKit device, designed for self-collection of samples, enabling a comprehensive health assessment of the entire female genital tract. Medite distributes its products through both direct sales channels and a network of distributors across significant markets, including the United States, China, Europe, and North Africa. Its primary clientele consists of histology and cytology laboratories within hospitals, research institutions, and independent diagnostic facilities. The company is based in Orlando, Florida.
What is Medite Cancer Diagnostics stock price today?▼
The current price of MDIT is $0.00 USD — it has increased by +0% in the past 24 hours. Watch Medite Cancer Diagnostics stock price performance more closely on the chart.
What is Medite Cancer Diagnostics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Medite Cancer Diagnostics stocks are traded under the ticker MDIT.
Is Medite Cancer Diagnostics stock price growing?▼
MDIT stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Medite Cancer Diagnostics has showed a +0% increase.
What is Medite Cancer Diagnostics market cap?▼
Today Medite Cancer Diagnostics has the market capitalization of 7,464.6
What were Medite Cancer Diagnostics earnings last quarter?▼
MDIT earnings for the last quarter are 0 USD per share, whereas the estimation was 0 USD resulting in a +NaN% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Medite Cancer Diagnostics revenue for the last year?▼
Medite Cancer Diagnostics revenue for the last year amounts to 13.63M USD.
What is Medite Cancer Diagnostics net income for the last year?▼
MDIT net income for the last year is -13.8M USD.
How many employees does Medite Cancer Diagnostics have?▼
As of June 15, 2026, the company has 69 employees.
In which sector is Medite Cancer Diagnostics located?▼
Medite Cancer Diagnostics operates in the Health & Wellness sector.
When did Medite Cancer Diagnostics complete a stock split?▼
The last stock split for Medite Cancer Diagnostics was on March 12, 2015 with a ratio of 1:100.
Where is Medite Cancer Diagnostics headquartered?▼
Medite Cancer Diagnostics is headquartered in Orlando, United States.